Abstract
Pancreatic cancer is characterized by its intrinsic resistance to cytotoxic agents. But the underlying molecular mechanism is unclear. Studies demonstrate that angiogenesis, presence of highly resistant cancer stem cells (CSCs), dysregulation of cell cycle and apoptosis are main aspects of mechanisms of pancreatic cancer chemoresistance. Interestingly, recent investigations of Wnt/β-catenin signaling suggest roles for the signaling in these four aspects and the pathogenesis of pancreatic cancer. Conceivably, the dysregulation of Wnt/β-catenin signaling pathway is involved in pancreatic cancer chemoresistance. Though researchers have proven it in some other cancer types, however, there is no direct evidence for this reasoning in pancreatic cancer. Designing effective experiment setups to define the function and mechanism of Wnt/β-catenin signaling in pancreatic cancer chemoresistance and subsequently targeting the signaling to improve the sensitivity of chemotherapy in pancreatic cancer require a full understanding of the molecular mechanisms of Wnt/β-catenin signaling pathway in angiogenesis, maintaining of highly resistant CSCs, regulation of cell cycle and apoptosis in pancreatic cancer.
Keywords: Wnt/β-catenin signaling, angiogenesis, chemoresistance, pancreatic cancer
Current Pharmaceutical Design
Title:Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer
Volume: 18 Issue: 17
Author(s): Jiujie Cui, Weihua Jiang, Shuyi Wang, Liwei Wang and Keping Xie
Affiliation:
Keywords: Wnt/β-catenin signaling, angiogenesis, chemoresistance, pancreatic cancer
Abstract: Pancreatic cancer is characterized by its intrinsic resistance to cytotoxic agents. But the underlying molecular mechanism is unclear. Studies demonstrate that angiogenesis, presence of highly resistant cancer stem cells (CSCs), dysregulation of cell cycle and apoptosis are main aspects of mechanisms of pancreatic cancer chemoresistance. Interestingly, recent investigations of Wnt/β-catenin signaling suggest roles for the signaling in these four aspects and the pathogenesis of pancreatic cancer. Conceivably, the dysregulation of Wnt/β-catenin signaling pathway is involved in pancreatic cancer chemoresistance. Though researchers have proven it in some other cancer types, however, there is no direct evidence for this reasoning in pancreatic cancer. Designing effective experiment setups to define the function and mechanism of Wnt/β-catenin signaling in pancreatic cancer chemoresistance and subsequently targeting the signaling to improve the sensitivity of chemotherapy in pancreatic cancer require a full understanding of the molecular mechanisms of Wnt/β-catenin signaling pathway in angiogenesis, maintaining of highly resistant CSCs, regulation of cell cycle and apoptosis in pancreatic cancer.
Export Options
About this article
Cite this article as:
Cui Jiujie, Jiang Weihua, Wang Shuyi, Wang Liwei and Xie Keping, Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer, Current Pharmaceutical Design 2012; 18 (17) . https://dx.doi.org/10.2174/13816128112092464
DOI https://dx.doi.org/10.2174/13816128112092464 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Protective Effect of α-ketobutyrate on Survival of Hippocampal Neurons Challenged with Hydrogen Peroxide Chemistry Mimicking Brain Ischemia
Current Pharmaceutical Analysis Classification of Sarcomas Using Bioinformatics and Molecular Profiling
Current Pharmaceutical Biotechnology Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry The DREAM of Pain Relief
Current Rheumatology Reviews The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Exploring the Anti-Neuroinflammatory Potential of Steroid and Terpenoid-Derived Phytochemicals to Combat Alzheimer's Disease
Current Pharmaceutical Design Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets CD248: Reviewing its Role in Health and Disease
Current Drug Targets Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry